HomeBUSINESS
BUSINESS

FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
(May.29.2017)

By Reiji Anasako

Japanese drug makers floundered both on the revenue and operating profit fronts in FY2016, which ended in March for most of these companies, as they faced drug price cuts at home and the stronger yen abroad. With healthcare cost pressure increasing globally year by year, how have Japanese makers performed in the recent years? This five-part series will delve into their latest financial results, with Part 1 looking into the growth trend since FY2010 ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 28.

News Calendar